Investigational Drug Details
| Drug ID: | D454 |
| Drug Name: | Bosutinib |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB06616 |
| DrugBank Description: | Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012. |
| PubChem ID: | 5328940 |
| CasNo: | 380843-75-4 |
| Repositioning for NAFLD: | Yes |
| SMILES: | COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl |
| Structure: |
|
| InChiKey: | UBPYILGKFZZVDX-UHFFFAOYSA-N |
| Molecular Weight: | 530.446 |
| DrugBank Targets: | Tyrosine-protein kinase ABL1; Tyrosine-protein kinase Lyn; Proto-oncogene tyrosine-protein kinase Src; Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2; Mitogen-activated protein kinase kinase kinase 2; Calcium/calmodulin-dependent protein kinase type II subunit gamma; Tyrosine-protein kinase Fgr; Tyrosine-protein kinase HCK; Tyrosine-protein kinase Tec; STE20-like serine/threonine-protein kinase |
| DrugBank MoA: | Bosutinib is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src-family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumour has been observed following administration of bosutinib. Bosutinib did not inhibit the T315I and V299L mutant cells. |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L2874 | NCT05831644 | PHASE1 | COMPLETED | YES | 2023-03-31 | 2024-11-12 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|